Alzheimer's Disease Prevention Trial - Full Text View

Purpose

This is a three-year study to determine if estrogens can prevent memory loss and Alzheimer's disease in women with a family history of Alzheimer's disease.

Condition	Intervention	Phase
Alzheimer Disease Memory Disorders	Drug: Estrogen Drug: Estrogen and Progesterone	Phase III

Genetics Home Reference related topics:

Alzheimer disease

MedlinePlus related topics:

Alzheimer's Disease Memory

Drug Information available for:

Progesterone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control

Official Title:	Alzheimer's Disease Prevention Trial. A Multi-Center, Randomized, Double-Blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.

Further study details as provided by National Institute on Aging (NIA):

Estimated Study Completion Date:

December 2010

Detailed Description:

PREventing Postmenopausal memory loss and Alzheimer's with Replacement Estrogens (PREPARE) is a double-blind-placebo controlled trial to determine whether estrogen (or estrogen and progesterone) can delay the onset of memory loss or Alzheimer's Disease in elderly women with a family history of the disease.

Eligibility

Ages Eligible for Study:	65 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy women 65 or older with a family history of memory problems not currently on estrogen.

Exclusion Criteria:

Significant neurological impairment
Current estrogen use
History of breast cancer

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000176

Locations


United States, Alabama
	University of Alabama
	Birmingham, Alabama, United States, 35294

United States, California
	University of California, Irvine
	Irvine, California, United States, 29697-4540

United States, Connecticut
	New England Center for Headache
	Stamford, Connecticut, United States, 06902-1249

United States, District of Columbia
	Howard University
	Washington, District of Columbia, United States, 20060

United States, Florida
	Lee Memorial Health System
	Fort Myers, Florida, United States, 33901
	West Florida Regional Medical Center
	Pensacola, Florida, United States, 32514
	North Broward Medical Center
	Pompano Beach, Florida, United States
	St. Mary's Medical Center
	West Palm Beach, Florida, United States, 33407
	Tallahassee Memorial Health Center
	Tallahassee, Florida, United States, 32308
	Wein Center
	Miami Beach, Florida, United States, 33140
	Mayo Clinic Jacksonville
	Jacksonville, Florida, United States, 32225

United States, Maryland
	Johns Hopkins Bayview Medical Center
	Baltimore, Maryland, United States, 21224

United States, New Jersey
	Neurology Group of Bergen County
	Ridgewood, New Jersey, United States, 07450

United States, New York
	Burke Medical Research Institute
	White Plains, New York, United States, 10605
	Columbia University
	New York, New York, United States, 10032
	Cornell Medical Center, New York Presbyterian Medical Center
	New York, New York, United States
	New York United Hospital Medical Center
	Port Chester, New York, United States, 10573

United States, North Carolina
	Duke University Medical Center
	Durham, North Carolina, United States, 27710

United States, Oklahoma
	Clinical Pharmaceutical Trials
	Tulsa, Oklahoma, United States, 74104-5428

United States, Rhode Island
	Butler Hospital, Rhode Island Hospital
	Providence, Rhode Island, United States, 02906

United States, South Carolina
	Medical University of South Carolina
	North Charleston, South Carolina, United States, 29406

United States, Virginia
	Eastern Virginia Medical School
	Norfolk, Virginia, United States, 23507-1912

Sponsors and Collaborators

National Institute on Aging (NIA)

Investigators


Principal Investigator:	Mary Sano, PhD	Mount Sinai School of Medicine

More Information

Publications of Results:

Aloysi A, Van Dyk K, Sano M. Women's cognitive and affective health and neuropsychiatry. Mt Sinai J Med. 2006 Nov;73(7):967-75. Review.

Other Publications:

Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996 Aug 17;348(9025):429-32.

Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997 Jun;48(6):1517-21.

Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL, Schofield P, Dooneief G, Gurland B, Mayeux R. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998 Feb;50(2):368-73.

Study ID Numbers:	IA0018, RO 1AG15922-01
First Received:	October 29, 1999
Last Updated:	September 19, 2007
ClinicalTrials.gov Identifier:	NCT00000176
Health Authority:	United States: Federal Government

Keywords provided by National Institute on Aging (NIA):

Alzheimer's disease

memory loss

Estrogen

Study placed in the following topic categories:

Progesterone

Alzheimer Disease

Central Nervous System Diseases

Brain Diseases

Neurodegenerative Diseases

Memory Disorders

Cognition Disorders

Signs and Symptoms

Delirium, Dementia, Amnestic, Cognitive Disorders

Mental Disorders

Neurologic Manifestations

Dementia

Neurobehavioral Manifestations

Amnesia

Delirium

Additional relevant MeSH terms:

Progestins

Physiological Effects of Drugs

Nervous System Diseases

Hormones, Hormone Substitutes, and Hormone Antagonists

Tauopathies

Hormones

Pharmacologic Actions

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	National Institute on Aging (NIA)
Information provided by:	National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:	NCT00000176